Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Vestis, Reckitt, and Tempus and Encourages Investors to Contact the Firm

Core Viewpoint - Class actions have been initiated against Vestis Corporation, Reckitt Benckiser Group, and Tempus AI, highlighting significant legal challenges and potential financial implications for these companies [1][4][6]. Group 1: Vestis Corporation (NYSE: VSTS) - The class period for Vestis is from May 2, 2024, to May 6, 2025, with a lead plaintiff deadline of August 8, 2025 [2]. - The complaint alleges that Vestis made misleading statements about its business growth capabilities, particularly regarding customer retention and revenue generation [2]. - Following a disappointing financial report on May 7, 2025, Vestis' stock price plummeted from $8.71 to $5.44, a decline of approximately 37.54% in one day [3]. Group 2: Reckitt Benckiser Group plc (OTC: RBGLY) - The class period for Reckitt is from January 13, 2021, to July 28, 2024, with a lead plaintiff deadline of August 4, 2025 [4]. - Over 500 lawsuits have been filed against Reckitt, alleging failure to warn about the risks associated with its cow's milk-based formula, Enfamil, which is linked to a serious intestinal disease in premature infants [4][5]. - The allegations include misleading statements regarding the safety of Reckitt's products and the potential impact on sales and legal exposure [5]. Group 3: Tempus AI, Inc. (NASDAQ: TEM) - The class period for Tempus is from August 6, 2024, to May 27, 2025, with a lead plaintiff deadline of August 11, 2025 [6]. - The complaint claims that Tempus failed to disclose significant issues, including inflated contract values and questionable business practices that could jeopardize its financial stability [6]. - Following a critical report from Spruce Point Capital Management on May 28, 2025, Tempus' stock price fell from $65.87 to $53.20, a decrease of 19.23% [7][8].